| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000033309 |
| Receipt No. | R000037972 |
| Scientific Title | The anti-inflammatory effect of fish oil enriched with EPA on cancer patients |
| Date of disclosure of the study information | 2018/07/07 |
| Last modified on | 2020/01/06 (Ver. 3) |
| Basic information | ||
| Public title | The anti-inflammatory effect of fish oil enriched with EPA on cancer patients | |
| Acronym | The effect of fish oil on cancer patients | |
| Scientific Title | The anti-inflammatory effect of fish oil enriched with EPA on cancer patients | |
| Scientific Title:Acronym | The effect of fish oil on cancer patients | |
| Region |
|
|
| Condition | ||
| Condition | Cancer patients | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the anti-inlflammatory effect of fish oil on cancer patients |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | CRP, IL-6, Albumin, Prealbumin
|
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Subjects ingest fish oil (EPA 498mg) and a high high-calorie jelly (energy 100kcal, protein 5g) for 8 weeks. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Carcinoma patients
Outpatients CRP over 0.30 mg/dl Aged 20 or older Oral Ingestible patients Patients who are expected to receive regular ambulatory treatment over 6 months |
|||
| Key exclusion criteria | Food allergies to fish, milk, soybean or gelatin
Taking supplement containing fish oil or EPA and DHA drugs Use of steroidal anti-inflammatory drugs Participation in another clinical study Patients who have difficulties to complete the trial Patients who are assessed by the principal investigator to be unsuitable to participate in the study |
|||
| Target sample size | 20 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Iga City General Hospital | ||||||
| Division name | Surgery | ||||||
| Zip code | |||||||
| Address | 831, Shizyuku-cho, Iga, Mie | ||||||
| TEL | 0595-24-1111 | ||||||
| qoujitanaka@yahoo.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Iga City General Hospital | ||||||
| Division name | Surgery | ||||||
| Zip code | |||||||
| Address | 831, Shizyuku-cho, Iga, Mie | ||||||
| TEL | 0595-24-1111 | ||||||
| Homepage URL | |||||||
| qoujitanaka@yahoo.co.jp | |||||||
| Sponsor | |
| Institute | Iga City General Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Morinaga Milk Industry Co, Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000037972 |